Type 2 diabetes mellitus
Conditions
Interventions
Patients who use no less than 30 units of standard concentration insulin glargine (100 units/mL) per shot will be switched to high concentration insulin glargine (300 units/mL) at same dosage, except
Sponsors
NHO Kyoto Medical Center, Diabetes Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes mellitus, who are hospitalized at or regularly visit the participating hospitals/clinics, who uses standard concentration insulin glargine for no less than 4 weeks, and who provides consent to change it to high concentration insulin glargine.
Exclusion criteria
Exclusion criteria: (1) Patients who already use high concentration insulin glargine. (2) Patients who are pregnant or under preconception care. (3) Patients to whom usage of insulin glargine is considered to be inappropriate for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the pain accompanied by injection | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the score regarding the easiness to use the injection device, adverse events, baseline HbA1c, age, sex, height, body weight, diabetic retinopathy, diabetic nephropathy, diabetic peripheral polyneuropathy, frequency of self monitoring of blood glucose, pharmacotherapy (insulin, other medication), place of injection. | — |
Countries
Japan
Contacts
Public ContactTakashi Murata
NHO Kyoto Medical Center Diabetes Center
Outcome results
None listed